Refile: Israel's BrainsWay Q2 revenue rises 35% to record high on higher shipments, utilization
REFILE-Israel's BrainsWay Q2 revenue rises 35% to record high on higher shipments, utilization Adds contact and disclaimer details at end of story
Aug 12 (Reuters) -
Overview
Israel neurostimulation device maker's Q2 revenue grew 35% yr/yr to record level
Adjusted EBITDA for Q2 more than doubled yr/yr, margin expanded to 20%
Company raised full-year 2026 revenue and EBITDA guidance
Outlook
BrainsWay raises FY 2026 revenue guidance to $68 mln-$70 mln from $66 mln-$68 mln
Company lifts FY 2026 adjusted EBITDA outlook to $13 mln-$14 mln from $12 mln-$14 mln
BrainsWay expects FY 2026 operating income margin of 13.5%-14%
Result Drivers
RECORD SYSTEM SHIPMENTS - Co shipped a record 125 Deep TMS systems in Q2, up 42% yr/yr
EXPANDING INSURER COVERAGE - Co said growth was fueled by expanding reimbursement coverage for SWIFT protocol
HIGHER UTILIZATION - Co cited increasing utilization throughout its installed base as a growth driver
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue |
| $17.11 mln |
|
Q2 EPS |
| $0.07 |
|
Q2 Net Income |
| $2.71 mln |
|
Q2 Gross Profit |
| $12.77 mln |
|
Q2 Operating Income |
| $2.39 mln |
|
Q2 Pretax Profit |
| $2.92 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Brainsway Ltd is $18.00, about 20.2% above its August 11 closing price of $14.98
Reuters Recommended Reads
Aug 11 - Neuronetics Q2 revenue beats estimates on Greenbrook clinic strength
Aug 11 - NeuroPace Q2 revenue slightly beats estimates
Aug 11 - Stereotaxis Q2 revenue misses estimates, dragged by system decline
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Brainsway
See all newsRefile: Israel's BrainsWay Q2 revenue rises 35% to record high on higher shipments, utilization
Brief: Brainsway Presents Positive Data From Largest Real-World Study Of Deep Tms™ In Patients With Comorbid Ptsd And Major Depressive Disorder
Brief: Brainsway Announces Minority-Stake Investment In Hopemark Health
Brief: Brainsway Announces New Minority-Stake Investment In Canadian Provider, Brainstim Health Inc.
Brief: Brainsway Announces Change In ADS-To-Ordinary Share Ratio